Profilaktika tromboembolicheskikh oslozhneniy u patsientov s khronicheskoy serdechnoy nedostatochnost'yu
- Authors: Napalkov D.A1, Sokolova A.A1, Zhilenko A.V1
-
Affiliations:
- Issue: No 13 (2013)
- Pages: 125-127
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282316
- ID: 282316
Cite item
Open Access
Access granted
Abstract
The article discusses the predisposing causes of pre-coagulant state in patients with chronic heart failure. Particular attention is given to patients with atrial fibrillation, in which the presence of heart failure is an additional risk factor for thromboembolic complications. The need for the prevention of thromboembolic complications in patients with left ventricular systolic dysfunction and stable sinus rhythm remains a topical issue.
Full Text
References
- Maisel WH, Stevenson LW Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D-8D.
- Boulanger CM, Vanhoutte PM. The endothelium: A pivotal role in health and cardiovascular disease. Houston, 1994:68.
- Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalites of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation, 2001; 103:1746-51.
- Hoffmeister A, Hetzel J, Sander S, et al. Plasma viscosity and fibrinogen in relation to haemodynamic findings in chronic congestive heart failure. Eur J Heart Failure 1999;1:293-95.
- Cleland JGF. Management of thrombosis in heart failure. Heart Failure. Philadelphia: DL Mann-Saunders, 2004:653-81.
- Batin PD, Wickens M, Mc Entergart D, et al. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995;16:1613-18.
- Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Amer Heart J 1994;127:607-12.
- Yamamoto K, Ikeda U, Turuhashi K, et al. The coagulation system is activated in dilated cardiomyopathy. J Amer Coll Cardiology 1995;25:1634-40.
- Cleland JGF. Management of thrombosis in heart failure. Heart Failure. Philadelphia: DL Mann-Saunders, 2004:653-81.
- Ridker PM, Gaboury CL. Conlin PR, et al. Stimulator of plasminogen activators inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the reninangiotensin system and fibrinolitic function. Circulation 1993;87:1969-73.
- Libby P, Simon DI. Inflammation and trombosis. The clot tkickens. Circulation 2001; 103:1718-20.
- Marjianowsky MU, van Lear M, Bras J, Becker AE. Chronic congestive heart failure associated with a phenotypic shift at intramiocardial endothelial cells. Circulation 1995;92:1491-98.
- Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibronolitic activity in patients with heart failure. Eur. Heart J. 1993;14:205-12.
- Rengo G, Pagano G, Squizzato A, Moja L, Femminella GD, et al. Oral Anticoagulation Therapy in Heart Failure Patients in Sinus Rhythm: A Systematic Review and MetaAnalysis. PLoS ONE 2013;8(1): e52952. doi:10. 1371/journal.
- Lip GY, Piotrponikowski P, et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost 2012;108(6):1009-22.
- Camm AJ, Kirchhof P, Lip GY, et al.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J 2010;31:2369-29.
- Banerjee A, Taillandier S, Olesen JB, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 2012;14:295-301.
Supplementary files
